Immunicon Corporation Files Universal Shelf Registration Statement

Any offering of securities covered by the universal shelfregistration statement will be made only by means of writtenprospectuses and prospectus supplements. If and when available, aprospectus may be obtained from Mr. James G. Murphy, Sr. VicePresident, Finance & Administration and Chief Financial Officer,Immunicon Corporation, 3401 Masons Mill Rd., Huntington Valley, PA19006.

A registration statement relating to these securities has beenfiled with the Securities and Exchange Commission but has not yetbecome effective. These securities may not be sold nor may offers tobuy be accepted prior to the time the registration statement becomeseffective. This press release shall not constitute an offer to sell ora solicitation of an offer to buy nor shall there be any sale of thesesecurities in any state in which such offer, solicitation or salewould be unlawful prior to registration or qualification under thesecurities laws of any such state.

About Immunicon Corporation

Immunicon Corporation is developing and commercializingproprietary cell- and molecular-based human diagnostic and lifescience research products with an initial focus on cancer diseasemanagement. Immunicon has developed platform technologies forselection and analysis of rare cells in blood, such as circulatingtumor cells and circulating endothelial cells that are important inmany diseases and biological processes. Immunicon's products andunderlying technology platforms also have application in the clinicaldevelopment of cancer drugs and in cancer research and may haveapplications in other fields of medicine, such as cardiovascular andinfectious diseases.

The information contained in this press release may include"forward-looking statements" within the meaning of the PrivateSecurities Litigation Reform Act of 1995. These forward-lookingstatements are often preceded by words such as "hope," "may,""believe," "anticipate," "plan," "expect," "intend," "assume," "will"and similar expressions and include, among others, any statements notof historical fact. Immunicon cautions investors not to place unduereliance on the forward-looking statements contained in this pressrelease. Forward-looking statements speak only as of the date of thispress release, reflect management's current expectations and involvecertain factors, such as risks and uncertainties that may cause actualresults to be far different from those suggested by Immunicon'sforward-looking statements. These factors include, but are not limitedto, risks and uncertainties associated with: Immunicon's dependence onVeridex, LLC, a Johnson & Johnson company, in the field of cancer cellanalysis; the risks and uncertainties associated with the arbitrationproceeding with Veridex given Immunicon's dependence on Veridex;Immunicon's capital and financing needs; research and development andclinical trial expenditures; commercialization of Immunicon's productcandidates; Immunicon's ability to use licensed products and to obtainnew licenses from third parties; Immunicon's ability to manage itsgrowth; obtaining necessary regulatory approvals; reliance on thirdparty manufacturers and suppliers; reimbursement by third party payorsto Immunicon's customers for Immunicon's products; risks anduncertainties associated with Immunicon's outstanding convertiblenotes and warrants; compliance with applicable manufacturingstandards; the ability to earn license and milestone payments underImmunicon's agreement with Veridex; retaining key management orscientific personnel; delays in the development of new products or toplanned improvements to Immunicon's products; effectiveness ofImmunicon's products compared to competitors' products; protection ofImmunicon's intellectual property and other proprietary rights;conflicts with the intellectual property of third parties; productliability lawsuits that may be brought against Immunicon; labor,contract or technical difficulties; and competitive pressures inImmunicon's industry. These factors are discussed in more detail inImmunicon's filings with the Securities and Exchange Commission.Except as required by law, Immunicon accepts no responsibility forupdating the information contained in this press release beyond thepublished date, whether as a result of new information, future eventsor otherwise, or for modifications made to this document by Internetor wire services.